Phase II Study of Front Line Therapy With Nivolumab and Salvage Nivolumab + Ipilimumab in Patients With Advanced Renal Cell Carcinoma. HCRN: GU16-260
Latest Information Update: 05 Jul 2024
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 04 Jun 2024 Results of molecular analysis of the HCRN GU16-260-Cohort A of first-line nivolumab and salvage nivo plus ipilimumab in patients with advanced clear cell renal cell carcinoma, presented at the 60th Annual Meeting of the American Society of Clinical Oncology.
- 27 Jan 2024 Results of an analysis assessing tumor-infiltrating CD163-positive macrophages and clinical outcomes presented at the 2024 Genitourinary Cancers Symposium
- 24 Oct 2023 Results of pooled meta analysis from NCT03203473, NCT03117309, NCT02917772 assessing to better inform the activity of N+I after N presented at the 48th European Society for Medical Oncology Congress